Reactome | Engelman, JA

Schema > Person > Entries

created	[InstanceEdit:9029752] Rothfels, Karen, 2017-11-22
dbId	9029753
displayName	Engelman, JA
firstname	Jeffrey A
initial	JA
publications	[LiteratureReference:9029754] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 [LiteratureReference:9700343] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK [LiteratureReference:9715259] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib [LiteratureReference:9701740] Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers [LiteratureReference:9716071] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer [LiteratureReference:9702243] Ceritinib in ALK-rearranged non-small-cell lung cancer [LiteratureReference:9714001] Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer [LiteratureReference:9700350] The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
schemaClass	Person
surname	Engelman

Cite Us!